GSK vs Regeneron Pharmaceuticals
GSK and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GSK and REGN compare
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus 4.1% for GSK).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with 17.5% at GSK.
Regeneron Pharmaceuticals pays a dividend yielding 0.39%; GSK does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 9 for GSK), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GSK | REGN |
|---|---|---|
| Size and price | ||
| Market cap | – | $98.5B |
| Share price | $50.41 | $952.40 |
| Change, 1 year | 4.7% | 37.0% |
| Change, 5 years | 0.24% | 48.0% |
| Beta (5Y) | 0.09 | 0.16 |
| Employees | 500K | 15K |
| StockData Score | ||
| Total score | 9 | 16 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 21.0× |
| P/S | – | 5.8× |
| P/B | – | 2.9× |
| EV/EBITDA | – | 17.0× |
| P/FCF | – | 25.7× |
| PEG | – | 7.61 |
| FCF yield | – | 3.9% |
| Fair value | – | $862.07 |
| Margin of safety | – | −10.5% |
| Growth | ||
| Revenue growth (TTM) | 4.1% | 18.6% (better) |
| Revenue growth, 5Y average | 6.0% | 11.0% (better) |
| Net income growth (TTM) | 122% (better) | 5.2% |
| EPS growth (TTM) | 123% (better) | 8.4% |
| EPS growth, 5Y average | −0.54% | 6.3% (better) |
| Profitability | ||
| Gross margin | 72.4% | – |
| Operating margin | 24.3% | 28.8% (better) |
| Net margin | 17.5% | 28.5% (better) |
| FCF margin | 19.6% | 22.6% (better) |
| Return on equity | 38.0% (better) | 14.9% |
| Return on invested capital | 23.4% (better) | 16.3% |
| Financial health | ||
| Debt / equity | 1.08 | 0.06 (better) |
| Net debt / EBITDA | 1.40 (better) | −1.36 |
| Interest coverage | 11.3× | 104× (better) |
| Current ratio | 0.82 | 3.35 (better) |
| Altman Z-score | – | 7.80 |
| Piotroski F-score | 9 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.39% |
| Payout ratio | 44.9% | 8.0% |
| Buyback yield | – | 2.0% |
| Shareholder yield | – | 2.4% |
| Ownership | ||
| Held by institutions | 8.0% | 88.5% |
| Held by insiders | 0.00% | 3.7% |
| Insider net buying, 12 months | – | −$57.4M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | – | 2.2% |
Go deeper
- GSK stock overview
- GSK income statement
- GSK valuation and score
- REGN stock overview
- REGN income statement
- REGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.